Followers | 49 |
Posts | 18364 |
Boards Moderated | 0 |
Alias Born | 02/26/2001 |
Tuesday, December 01, 2020 6:17:52 PM
To access the live and archived webcast of the presentation, please visit the Events & Presentations page of the G1 website.
About G1 Therapeutics
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer. The company is developing and advancing two novel therapies: trilaciclib is a first-in-class therapy designed to improve outcomes for patients being treated with chemotherapy; rintodestrant is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. In 2020, the company out-licensed global development and commercialization rights to its differentiated oral CDK4/6 inhibitor, lerociclib.
Recent GTHX News
- G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024 • GlobeNewswire Inc. • 04/17/2024 01:00:34 PM
- G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/04/2024 02:30:30 PM
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/01/2024 08:20:26 PM
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/01/2024 09:20:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 11:35:25 AM
- G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights • GlobeNewswire Inc. • 02/28/2024 11:30:52 AM
- G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/27/2024 01:30:01 PM
- G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024 • GlobeNewswire Inc. • 02/15/2024 01:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 11:14:36 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/12/2024 09:42:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 09:19:42 PM
- G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee • GlobeNewswire Inc. • 02/12/2024 09:05:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/09/2024 09:19:03 PM
- G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/08/2024 11:45:52 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 11:30:32 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 11:04:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 11:03:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 11:03:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 11:03:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 11:02:52 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 11:02:02 AM
- G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/03/2024 02:00:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 12:44:10 AM
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 01/02/2024 09:51:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/13/2023 09:45:43 PM
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM